NEUROCRINE BIOSCIENCES INC

NEUROCRINE BIOSCIENCES INC (NBIX) is a publicly traded US company. Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

The company reports trailing twelve-month revenue of $96.91M and net income of $197.90M.

Key metrics include a return on equity of 5.8%, a debt-to-equity ratio of 0.44.

Investors tracking NBIX can follow price movements, analyst estimates, and fundamental changes directly through FINOTAUR's research tools.